WST vs ZBH
WST: Global leader in injectable drug containment and delivery systems serving biopharmaceutical and medical device manufacturers with primary packaging, drug delivery devices, and contract manufacturing. ZBH: A global leader in musculoskeletal healthcare, providing a comprehensive portfolio of reconstructive implants, sports medicine, and trauma technologies to restore patient mobility.
Side-by-side fundamentals
| Metric | WST | ZBH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $358.41 | $88.68 | |
| Market cap as of 2026-07-23 | $25.8B | $17.5B | |
| P/E as of 2026-07-23 | 47.55 | 22.96 | ZBH lower |
| PEG as of 2026-07-23 | 3.24 | 4.19 | WST lower |
| Net margin as of 2026-07-23 | +16.9% | +9.1% | WST higher |
| Gross margin as of 2026-07-23 | +36.3% | +70.0% | ZBH higher |
| Operating margin as of 2026-07-23 | +20.3% | +14.0% | WST higher |
| ROE as of 2026-07-23 | +17.9% | +6.0% | WST higher |
| ROA as of 2026-07-23 | +13.2% | +3.3% | WST higher |
| Debt / equity as of 2026-07-23 | 0.07 | 0.59 | WST lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.2% | +9.2% | WST higher |
| Revenue CAGR (3y) SEC XBRL | +2.1% | +5.9% | ZBH higher |
| Dividend yield as of 2026-07-23 | +0.3% | +1.0% | ZBH higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-23 | 1.12 | 0.47 | |
| 1-year return as of 2026-07-22 close | +63.7% | -8.1% | WST higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.